Management and Prevention of Myeloma Bone Disease

Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Multiple Myeloma

Myeloma bone disease is a consequence of increased osteoclastic activity, and agents that inhibit osteoclasts are an important component of myeloma therapy.[9] The bisphosphonates pamidronate and zoledronate are used most often, via IV infusion, but the RANKL monoclonal antibody inhibitor denosumab, given subcutaneously, is also effective, especially when renal dysfunction precludes the use of bisphosphonates.[8,9]

Source links and citations

Continue within this section

Zoledronate (bisphosphonate) →Pamidronate (bisphosphonate) →Denosumab (RANKL inhibitor) →Radiation therapy for bone lesions →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice